From a non experts view, if the brain makes the decision, then if the part of the brain which controls this is disabled we will not feel pain. Hence developing a medication that will target the area which controls the pain. However with DDD if you control the pain you still have the problem of mobility.
I do not agree with your concluding comment, while the Phase I is more for safety the FDA will approve only a product if it passes safety and efficacy standards.
Back pain stem cell injection, page-129
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.085(6.83%) |
Mkt cap ! $1.575B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $12.75M | 9.481M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 7615 | $1.33 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 9548 | 3 |
View Market Depth
| Last trade - 13.37pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |